FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281630256> ?p ?o ?g. }

• W4281630256 endingPage "938" @default.
• W4281630256 startingPage "929" @default.
• W4281630256 abstract "Pembrolizumab demonstrated durable antitumor activity in 233 patients with previously treated advanced microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors in the phase II multicohort KEYNOTE-158 (NCT02628067) study. Herein, we report safety and efficacy outcomes with longer follow-up for more patients with previously treated advanced MSI-H/dMMR noncolorectal cancers who were included in cohort K of the KEYNOTE-158 (NCT02628067) study.Eligible patients with previously treated advanced noncolorectal MSI-H/dMMR solid tumors, measurable disease as per RECIST v1.1, and Eastern Cooperative Oncology Group performance status of 0 or 1 received pembrolizumab 200 mg Q3W for 35 cycles or until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) as per RECIST v1.1 by independent central radiologic review.Three hundred and fifty-one patients with various tumor types were enrolled in KEYNOTE-158 cohort K. The most common tumor types were endometrial (22.5%), gastric (14.5%), and small intestine (7.4%). Median time from first dose to database cut-off (5 October 2020) was 37.5 months (range, 0.2-55.6 months). ORR among 321 patients in the efficacy population (patients who received ≥1 dose of pembrolizumab enrolled ≥6 months before the data cut-off date) was 30.8% [95% confidence interval (CI) 25.8% to 36.2%]. Median duration of response was 47.5 months (range, 2.1+ to 51.1+ months; '+' indicates no progressive disease by the time of last disease assessment). Median progression-free survival was 3.5 months (95% CI 2.3-4.2 months) and median overall survival was 20.1 months (95% CI 14.1-27.1 months). Treatment-related adverse events (AEs) occurred in 227 patients (64.7%). Grade 3-4 treatment-related AEs occurred in 39 patients (11.1%); 3 (0.9%) had grade 5 treatment-related AEs (myocarditis, pneumonia, and Guillain-Barre syndrome, n = 1 each).Pembrolizumab demonstrated clinically meaningful and durable benefit, with a high ORR of 30.8%, long median duration of response of 47.5 months, and manageable safety across a range of heavily pretreated, advanced MSI-H/dMMR noncolorectal cancers, providing support for use of pembrolizumab in this setting." @default.
• W4281630256 created "2022-06-13" @default.
• W4281630256 creator A5001115937 @default.
• W4281630256 creator A5009198553 @default.
• W4281630256 creator A5009613920 @default.
• W4281630256 creator A5018536695 @default.
• W4281630256 creator A5020672869 @default.
• W4281630256 creator A5027371764 @default.
• W4281630256 creator A5029073714 @default.
• W4281630256 creator A5029398339 @default.
• W4281630256 creator A5030448011 @default.
• W4281630256 creator A5039952118 @default.
• W4281630256 creator A5048013287 @default.
• W4281630256 creator A5053725787 @default.
• W4281630256 creator A5059766169 @default.
• W4281630256 creator A5065206480 @default.
• W4281630256 creator A5080562953 @default.
• W4281630256 creator A5084542730 @default.
• W4281630256 creator A5085693851 @default.
• W4281630256 date "2022-09-01" @default.
• W4281630256 modified "2023-10-14" @default.
• W4281630256 title "Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study" @default.
• W4281630256 cites W1940241680 @default.
• W4281630256 cites W1984642649 @default.
• W4281630256 cites W2198093519 @default.
• W4281630256 cites W2287918349 @default.
• W4281630256 cites W2622499649 @default.
• W4281630256 cites W2739132742 @default.
• W4281630256 cites W2904444972 @default.
• W4281630256 cites W2912271356 @default.
• W4281630256 cites W2925815206 @default.
• W4281630256 cites W2944675676 @default.
• W4281630256 cites W2945043419 @default.
• W4281630256 cites W2970410478 @default.
• W4281630256 cites W2983284890 @default.
• W4281630256 cites W2984359187 @default.
• W4281630256 cites W2991389580 @default.
• W4281630256 cites W3026325163 @default.
• W4281630256 cites W3064380789 @default.
• W4281630256 cites W3110528877 @default.
• W4281630256 cites W3120340770 @default.
• W4281630256 cites W3121662262 @default.
• W4281630256 cites W3133054796 @default.
• W4281630256 cites W3139884936 @default.
• W4281630256 cites W3196423917 @default.
• W4281630256 doi "https://doi.org/10.1016/j.annonc.2022.05.519" @default.
• W4281630256 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35680043" @default.
• W4281630256 hasPublicationYear "2022" @default.
• W4281630256 type Work @default.
• W4281630256 citedByCount "64" @default.
• W4281630256 countsByYear W42816302562014 @default.
• W4281630256 countsByYear W42816302562022 @default.
• W4281630256 countsByYear W42816302562023 @default.
• W4281630256 crossrefType "journal-article" @default.
• W4281630256 hasAuthorship W4281630256A5001115937 @default.
• W4281630256 hasAuthorship W4281630256A5009198553 @default.
• W4281630256 hasAuthorship W4281630256A5009613920 @default.
• W4281630256 hasAuthorship W4281630256A5018536695 @default.
• W4281630256 hasAuthorship W4281630256A5020672869 @default.
• W4281630256 hasAuthorship W4281630256A5027371764 @default.
• W4281630256 hasAuthorship W4281630256A5029073714 @default.
• W4281630256 hasAuthorship W4281630256A5029398339 @default.
• W4281630256 hasAuthorship W4281630256A5030448011 @default.
• W4281630256 hasAuthorship W4281630256A5039952118 @default.
• W4281630256 hasAuthorship W4281630256A5048013287 @default.
• W4281630256 hasAuthorship W4281630256A5053725787 @default.
• W4281630256 hasAuthorship W4281630256A5059766169 @default.
• W4281630256 hasAuthorship W4281630256A5065206480 @default.
• W4281630256 hasAuthorship W4281630256A5080562953 @default.
• W4281630256 hasAuthorship W4281630256A5084542730 @default.
• W4281630256 hasAuthorship W4281630256A5085693851 @default.
• W4281630256 hasBestOaLocation W42816302561 @default.
• W4281630256 hasConcept C104317684 @default.
• W4281630256 hasConcept C121608353 @default.
• W4281630256 hasConcept C126322002 @default.
• W4281630256 hasConcept C141071460 @default.
• W4281630256 hasConcept C143998085 @default.
• W4281630256 hasConcept C180754005 @default.
• W4281630256 hasConcept C185592680 @default.
• W4281630256 hasConcept C203092338 @default.
• W4281630256 hasConcept C2777088508 @default.
• W4281630256 hasConcept C2777701055 @default.
• W4281630256 hasConcept C2778822529 @default.
• W4281630256 hasConcept C2779134260 @default.
• W4281630256 hasConcept C2779767149 @default.
• W4281630256 hasConcept C2779984678 @default.
• W4281630256 hasConcept C2780057760 @default.
• W4281630256 hasConcept C2908647359 @default.
• W4281630256 hasConcept C31760486 @default.
• W4281630256 hasConcept C44249647 @default.
• W4281630256 hasConcept C535046627 @default.
• W4281630256 hasConcept C55493867 @default.
• W4281630256 hasConcept C61320498 @default.
• W4281630256 hasConcept C71924100 @default.
• W4281630256 hasConcept C72563966 @default.
• W4281630256 hasConcept C99454951 @default.
• W4281630256 hasConceptScore W4281630256C104317684 @default.
• W4281630256 hasConceptScore W4281630256C121608353 @default.

• next